Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies

Margaret L MacMillan; Mark C Walters; Eliane Gluckman

doi:10.1053/j.seminhematol.2009.10.004

Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies

Semin Hematol. 2010 Jan;47(1):37-45. doi: 10.1053/j.seminhematol.2009.10.004.

Authors

Margaret L MacMillan¹, Mark C Walters, Eliane Gluckman

Affiliation

¹ Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA. macmi002@umn.edu

PMID: 20109610
DOI: 10.1053/j.seminhematol.2009.10.004

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure remains a significant problem, UCB transplantation (UCBT) using the optimal conditioning regimen can be a salvage treatment for patients without a suitable BM donor and warrants evaluation in further prospective studies.

Publication types

Review

MeSH terms

Blood Banks
Blood Donors / supply & distribution
Bone Marrow Diseases / surgery*
Cord Blood Stem Cell Transplantation* / adverse effects
Hematopoietic Stem Cell Transplantation* / adverse effects
Hemoglobinopathies / surgery*
Humans
Patient Selection
Transplantation, Homologous
Treatment Outcome